The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

Several presentations at CROI 2024 addressed whether HIV is starting to develop resistance to the integrase inhibitor dolutegravir, one of the most widely used antiretrovirals in the world. In World ...

Viral load results are also important for other aspects of patient care, but there are no clear data showing the clinical relevance of results below 200 copies/ml. One exception is that a viral load ...

BHIVA recommends that people aged 40 and over should be offered a statin irrespective of lipid levels or estimated cardiovascular risk. People with HIV aged 40 and over with an estimated 10-year risk ...

Using a computer model, researchers at University College London have found that there is no realistic chance in the UK of reaching the 'Ending AIDS' goal for 2030 that was first set by the United ...

Budigalimab, a monoclonal antibody that blocks the PD-1 receptor on immune cells, was associated with delayed HIV rebound or sustained low viral load in a majority of people who interrupted ...

In some cases, HIV can bypass the barrier that encases the brain and cerebrospinal fluid which can contribute to brain inflammation and neurocognitive symptoms. However, diagnosing this viral ‘escape’ ...

Lenacapavir, the first HIV capsid inhibitor, has a long half-life in the body, allowing it to be administered by subcutaneous injection just once every six months. It also comes in an oral formulation ...

A man dubbed the 'Geneva patient' appears to be the latest person cured of HIV after a stem cell transplant for cancer treatment. Unlike the other five known cases, however, he received stem cells ...